Proteomics International Secures licence for oesophageal cancer biomarkers
- Proteomics International Laboratories (PIQ) secures a worldwide licence for oesophageal cancer biomarkers
- The licence agreement to commercialise biomarkers that test for oesophageal adenocarcinoma has been signed with the QIMR Berghofer Medical Research Institute
- Under the contract, QIMR’s intellectual property in the biomarkers will become licensed exclusively to Prote omics, which the company will use to develop and commercialise a simple blood test for the cancer
- The company says it will now undertake additional studies to confirm the diagnostic performance of the potential new blood test, which will take approximately six months
- The company International is up 2.56 per cent, trading at 80 cents at 2:03 pm AEST
